Table 1.
Summary of radiation-induced gliomas reported in previous studies.
| Reference | Number of cases | Primary malignancy | Latency period (years) | Age at RIG diagnosis (years) | Gender ratio (m:f) | Death (y/number of cases) | OS (months) | PDGFRA status | CDKN2A/B status | Further genetic alterations |
|---|---|---|---|---|---|---|---|---|---|---|
| Brat et al.6 | 6 | ALL, Pineal tumors, Lymphoblastic Lymphoma, Pituary adenoma, Rhabdomyosarkoma, Craniopharyngeoma | 5–23 | 9–60 | 2:1 | N.D. | N.D. | N.D. | N.D. | – |
| Donson et al.7 | 5 | Burkitt’s Lymphoma, MB, low-grade astrocytoma, ependymoma, ALL | 3–15 | 11–23 | 3:2 | 5/5 | 1–10 | Overexpressed | N.D. | – |
| Lopez et al.20 | 12 | Craniopharyngioma, Germinoma, Medulloblastoma, Pineocytoma, ALL, Hodgkin’s Lymphoma | 4–41 | 7–48 | 8:4 | 5/7 | <24 | Amplified in 42%, mutated in one case | Loss in 33% | Amplified CDK4 in 33%, amplified MET in 17% |
| Nakao et al.13 | 4 | Pituary adenoma, Meduloblastoma, Craniopharyngioma, PNET | 22–29 | 32–55 | 3:1 | 4/4 | 11–30 | N.D. | N.D. | IDH1 and H3F3A wild type |
| Paugh et al.21 | 10 | ALL, Germinoma, MB, Ependymoma | N.A. | 8–19 | N.A. | 7/9 | 8–91 | Amplified in 50% | Loss in 50% | 1q gain (50%), 1p loss (50%), 13q loss (70%) |
| Phi et al.22 | 5 | Medulloblastoma (SHH, Group3) | 4.3–10 | 9.2–17 | 2:3 | N.D. | N.D | Missense mutation, gene fusion | N.D. | TP53 (somatic mutations or 17p loss), 7q gain (EZH2) |
| Romeike et al.16 | 7 | ALL, MB | 7–14 | 9–19 | 4:3 | 7/7 | 9–27 | N.D. | N.D | – |
| Walter et al.18 | 7 | ALL | 7–14 | 10–24 | 4:3 | 5/7 | 0.1–93 | N.D. | N.D. | – |
OS overall survival, N.D. not determined.